DXRX logo
Lab Talks & Webinars

Biomarkers in Colorectal Cancer: Daily Struggles

31 Aug 2022

The aim of this Lab Talk is to understand and review the rationale for biomarker assessment in colorectal cancer from a hereditary, therapeutic and diagnostic and prognostic standpoints.

Lab Talks: Biomarkers in Colorectal Cancer Daily Struggless_promotional_graphic

Date and time: Thursday September 29th, 2022 1pm (EST)

Duration: 1 hour (total)

Agenda:
1.00-1.05: Welcome and introduction of Diaceutics and speaker Dr David Schaeffer

1.05-1.45: Biomarkers in Colorectal Cancer – Daily Struggles by Dr David Schaeffer

1.45-2.00: Q&A and discussion

Note: This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology (ASCP) as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program and any other boards that recognize this credit.

Click the register button below.
Register here

Speaker name: Dr. David Schaeffer, MD FRCPC

Speaker title: Head & Medical Director, Dept of Pathology & Laboratory Medicine, Vancouver

Dr. David Schaeffer MD FRCPC Head & Medical Director, Dept of Pathology & Laboratory Medicine, Vancouver – Acute Services

Dr. Schaeffer is an associate professor in the Department of Pathology & Laboratory Medicine at University of British Columbia and the Head of the Division of Anatomic Pathology at Vancouver General Hospital (VGH) where he practices as a gastrointestinal pathologist. Dr. Schaeffer obtained his medical degree from the Johannes Gutenberg University of Mainz, Germany. After a residency program in Anatomical Pathology in Vancouver he completed his gastrointestinal pathology fellowship at Mount Sinai Hospital in Toronto. Dr. Schaeffer is a co-director of Pancreas Centre BC and also heads the Gastrointestinal Biobank (GIBB) at VGH. He has an active research program focusing predominately on translational research in colonic and pancreatic cancer.